Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

February 25, 2020February 26, 2020

CAR NK Cells Demonstrate High Response Rate and Safety in Lymphoma and Leukemia, Early Trial Shows

News

Natural killer (NK) cells — a type of immune system cell — engineered with a chimeric antigen receptor against CD19 completely eliminated tumors in 64% of people with non-Hodgkin’s lymphoma ... Read more

December 12, 2019December 12, 2019

Health Canada Approves Adcetris-Chemo Combo for Initial Peripheral T-cell Lymphoma Treatment

News

Health Canada has expanded its approval of Adcetris (brentuximab vedotin) in combination with a chemotherapy regimen for the first-line treatment of peripheral T-cell lymphomas expressing the CD30 marker. The approval is ... Read more

October 29, 2019

Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest

News

Treatment with Copiktra (duvelisib) doubles response rates compared with Arzerra (ofatumumab), and significantly extends the time until disease progression or death in people with chronic lymphocytic leukemia (CLL) or small ... Read more

October 1, 2019October 1, 2019

Radiation Prior to CAR T-cell Therapy in Non-Hodgkin’s Lymphoma May Ease Side Effects, Study Suggests

News

Treating non-Hodgkin’s lymphoma patients with radiation before giving them CAR T-cell therapy may lessen the likelihood of them experiencing toxic side effects, a small study suggests. This finding was detailed at the ... Read more

June 14, 2019

ME-401 Experimental Compound Reduces Tumor Burden in Follicular Lymphoma, Phase 1 Trial Shows

News

MEI Pharma‘s experimental compound ME-401 reduced tumor burden in 80% of patients with relapsed or refractory follicular lymphoma in a Phase 1 trial, the company said. Responses were comparable among ... Read more

June 7, 2019

Triple Therapy Combo Effective in Treating DLBCL Subtype, Data Suggest

News

People with the non-germinal center subtype of diffuse large B-cell lymphoma (non-GCB DLBCL) respond well to initial treatment with Rituxan (rituximab), Imbruvica (ibrutinib), and Revlimid (lenalidomide) — so well that ... Read more

March 5, 2019

PET Monitoring Can Be Used to Tailor Hodgkin’s Treatment, Trial Suggests

News

Monitoring Hodgkin’s lymphoma patients with positron-emission tomography (PET) scans during chemotherapy can help identify those who respond early to a more intense chemotherapy regimen and switch them to a softer, ... Read more

February 19, 2019

Poteligeo Proves Safe, Effective for ATL Patients in Clinical Setting

News

Poteligeo (mogamulizumab), an approved treatment for relapsed or refractory adult T-cell leukemia-lymphoma (ATL) patients in Japan, is also safe and effective in a real-world clinical setting, a postmarketing surveillance study found. ... Read more

February 18, 2019

Opdivo Effective for Relapsed/Refractory Classical Hodgkin’s Lymphoma, Meta-analysis Suggests

News

Immune checkpoint inhibitor Opdivo (nivolumab) appears to be more effective at treating patients with relapsed or refractory classical Hodgkin’s lymphoma than other therapies, a meta-analysis suggests. The study, “Efficacy of ... Read more

January 25, 2019

2 Chemo Regimens Used Before Stem Cell Transplant Have Similar Effectiveness, Study Finds

News

A chemotherapy regimen called modified busulfan-cyclophosphamide (mBuCy) — which consists of busulfan, cyclophosphamide, semustine, and cytarabine — is as effective as standard chemotherapy in preparing lymphoma patients for a stem cell ... Read more